ENDPOINTS

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

Merck KGaA is spending $85 million to tap global commercialization rights to pimicotinib, a candidate for non-malignant tumors that it licensed from China’s Abbisko Therapeutics in 2023. The German drugmaker will be responsible for selling ...

Mar 28, 2025 - 11:55
 0
Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug
Merck KGaA is spending $85 million to tap global commercialization rights to pimicotinib, a candidate for non-malignant tumors that it licensed from China’s Abbisko Therapeutics in 2023. The German drugmaker will be responsible for selling ...
Read More

Tags:

Previous Article

5 ways to match work skills with tomorrow's jobs 

Next Article

Looking for a job? Find your community first

Related Posts

AbbVie wins FDA approval for new antibiotic

AbbVie wins FDA approval for new antibiotic

Feb 9, 2025  0

FDA's biologics chief stresses need for vaccine transmission data

FDA's biologics chief stresses need for vaccine transmi...

Mar 24, 2025  0

Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says

Pfizer’s manufacturing arm at risk from Trump tariffs i...

Feb 19, 2025  0